Last reviewed · How we verify
Statin
At a glance
| Generic name | Statin |
|---|---|
| Also known as | 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, Atorvastatin, atorvastatin, HMG-coA reductase Inhibitor, rosuvastatin |
| Sponsor | Saint-Joseph University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Using Big Data to Conduct Innovative Cardiovascular Clinical Trials (NA)
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (PHASE2)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Statin CI brief — competitive landscape report
- Statin updates RSS · CI watch RSS
- Saint-Joseph University portfolio CI